SCHEMBL6475739

SCHEMBL6475739

O=S(=O)(Nc1cccc(CCOCc2ccc(Oc3ccccc3)cc2)c1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.48
CYSLTR2 Q9NS75 1/20 0.44
CYSLTR1 Q9Y271 1/20 0.44
PGR P06401 3/20 0.41
CA2 P00918 1/20 0.41
AR P10275 2/20 0.40
NR3C1 P04150 1/20 0.40
ESR2 Q92731 1/20 0.40
NAAA Q02083 1/20 0.40
FFAR1 O14842 1/20 0.39
HTR6 P50406 5/20 0.39
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
CACNA1B Q00975 1/20 0.38
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482251 0.88 CYSLTR2 (0.51) CYSLTR2CYSLTR1ARFFAR1DRD2
SCHEMBL6475312 0.86 CA2 (0.40) CYSLTR2CYSLTR1CA2HTR6PTGS1
SCHEMBL6475717 0.85 CA2 (0.43) PTPN1CYSLTR2CYSLTR1CA2HTR6
SCHEMBL6474786 0.85 LTB4R (0.41) PTPN1CYSLTR2CYSLTR1CA2PTGS1
SCHEMBL6475351 0.83 IKBKB (0.46) CYSLTR2CYSLTR1CA2PTGS1PTGS2
SCHEMBL6479679 0.83 KDM1A (0.42) CYSLTR2CYSLTR1CA2PTGS1PTGS2
SCHEMBL6483863 0.83 PPARA (0.47) CYSLTR2CYSLTR1CA2PTGS1PTGS2
SCHEMBL6482520 0.83 KIF11 (0.46) CYSLTR2CYSLTR1CA2AR
SCHEMBL6482540 0.81 CYSLTR2 (0.42) CYSLTR2CYSLTR1CA2FFAR1PTGS1
SCHEMBL6474092 0.81 PPARA (0.41) CYSLTR2CYSLTR1CA2PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 PTPN1 54/4885CYSLTR2 4703/4885CYSLTR1 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.